Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).
Melanoma
DRUG: CC-122|DRUG: Nivolumab
Objective Response Rate of CC-122 in Combination With Nivolumab, Objective Response Rate of CC-122 in combination with Nivolumab in both anti-PD1 therapy naive advanced melanoma as well as anti-PD1 therapy refractory melanoma (primary refractory or progressing after an initial response or stable disease), Up to 52 weeks
Number of Participants Who Experience Treatment Related Adverse Events, All Adverse Events and Serious Adverse events will be collected and collated according to grade and frequency. This will include all events considered possibly, probably or definitely related to study therapy., Up to 52 weeks|Tumor Response, Tumor response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and and iRECIST (Response Evaluation Criteria in Solid Tumors in immunotherapy) guidelines v1.1. Results will be indicated as number of participants with evaluable tumor response., Up to 52 weeks|Progression Free Survival, Progression free survival will be calculated from the start of study therapy till the first documentation of disease progression, death, or change of treatment. Subjects receiving ongoing therapy at the time of data analysis will be censored, Up to 24 months|Overall Survival, Overall survival will be calculated from the start of therapy till death from any cause. Subjects alive at the time of data analysis will be censored., Up to 24 months
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).